首页> 外文OA文献 >Comparative Study of Different Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors Affecting Lung Cancer Cell Lines Stably Overexpressing EGFR Mutations

【2h】

Comparative Study of Different Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors Affecting Lung Cancer Cell Lines Stably Overexpressing EGFR Mutations

机译：不同表皮生长因子受体（EGFR）的对比研究 - 纯血清酶抑制剂，影响EGFR突变的肺癌细胞系

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Tomohiro Ariyama; Yuichiro Kanno; Sonomi Takizawa; Kiyomitsu Nemoto; Toshihiro Ishii;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 22:02:25

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations [J] . Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Investigational new drugs. . 2019,第6期

机译：I阶段研究Tas-121，第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，患有EGFR突变的非小细胞肺癌患者
3. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109) [J] . Hattori Yoshihiro, Satouchi Miyako, Shimada Temiko, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第2期

机译：一线EGFR酪氨酸激酶抑制剂失败后，具有表皮生长因子受体（EGFR）突变的非鳞状非小细胞肺癌患者中贝伐单抗联合卡铂和紫杉醇的2期研究（HANSHIN Oncology Group 0109 ）
4. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: An exploratory study [J] . LeeJ.K., ShinJ.-Y., KimS., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第8期

机译：具有TKI敏感EGFR突变的非小细胞肺癌患者对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）的主要耐药性：一项探索性研究
5. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
6. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
7. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界观测性前瞻性研究以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：悠久的研究
8. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：一个现实世界，观测的，前瞻性研究，评估在一线治疗的前进过程中的表皮生长因子受体（EGFR）突变的分子流行病学与EGFR突变阳性局部先进或者的第一代或第二代EGFR酪氨酸激酶抑制剂转移性非小细胞肺癌：“悠久”的研究

Comparative Study of Different Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors Affecting Lung Cancer Cell Lines Stably Overexpressing EGFR Mutations

著录项

相似文献

相关主题

期刊订阅